By: dfitzgerald
Executive Summary
NHeLP letter to the Senate Finance Committee in response to the request for public comment on policy issues including the financial impact of high prices of breakthrough drugs, data on prescription drug costs, and ensuring patient access, particularly for low income and vulnerable populations. Commments follow after an 18 month investigation into Gilead and the pricing of breakthrough treatments for hepatitis C, including Sovaldi and Harvoni.
